Current approach to diagnosis and management of acute renal failure in myeloma patients
- PMID: 22920640
- DOI: 10.1053/j.ackd.2012.06.001
Current approach to diagnosis and management of acute renal failure in myeloma patients
Abstract
Renal impairment is a serious complication of multiple myeloma. The primary cause of renal failure in myeloma is damage to the kidney by excessive amounts of light chain produced by the myeloma tumor, giving rise to cast nephropathy (myeloma kidney), although there are several other important precipitants. Significantly poor prognosis is observed in patients who do not recover their renal function; however, with the advent of more effective therapies and a greater understanding of the pathogenesis of the underlying process, it has become possible to reverse renal impairment in greater numbers of patients. Determining whether the renal impairment is due to cast nephropathy should be the first priority, and once the diagnosis is confirmed, appropriate treatment should be initiated without delay. Reduction of serum free light chain is the key to recovery of renal function in these patients. The role of chemotherapy and extracorporeal removal of light chain are discussed.
Copyright © 2012 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Haemodialysis using high cut-off dialysers for treating acute renal failure in multiple myeloma.Nefrologia. 2012;32(1):35-43. doi: 10.3265/Nefrologia.pre2011.Nov.11094. Nefrologia. 2012. PMID: 22294003 English, Spanish.
-
Myeloma kidney: improving clinical outcomes?Adv Chronic Kidney Dis. 2012 Sep;19(5):342-51. doi: 10.1053/j.ackd.2012.03.001. Adv Chronic Kidney Dis. 2012. PMID: 22920645 Review.
-
[Withdrawal of maintenance dialysis in a patient with diagnosed multiple myeloma and renal failure as a consequence of effective anti-tumor treatment].Przegl Lek. 2010;67(7):547-50. Przegl Lek. 2010. PMID: 21387773 Polish.
-
Management options for cast nephropathy in multiple myeloma.Curr Opin Nephrol Hypertens. 2010 Nov;19(6):550-5. doi: 10.1097/MNH.0b013e32833ef72c. Curr Opin Nephrol Hypertens. 2010. PMID: 20827195 Review.
-
Impact of free light chain hemodialysis in myeloma cast nephropathy: a case-control study.Hemodial Int. 2011 Oct;15(4):538-45. doi: 10.1111/j.1542-4758.2011.00587.x. Epub 2011 Aug 16. Hemodial Int. 2011. PMID: 22111823
Cited by
-
Severe renal impairment as an adverse prognostic factor for survival in newly diagnosed multiple myeloma patients.J Clin Lab Anal. 2020 Sep;34(9):e23416. doi: 10.1002/jcla.23416. Epub 2020 Jul 25. J Clin Lab Anal. 2020. PMID: 32710448 Free PMC article.
-
Myeloma light chain cast nephropathy, a review.J Nephrol. 2019 Apr;32(2):189-198. doi: 10.1007/s40620-018-0492-4. Epub 2018 May 5. J Nephrol. 2019. PMID: 29730782 Review.
-
Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials.Blood Adv. 2018 Jul 10;2(13):1633-1644. doi: 10.1182/bloodadvances.2017015545. Blood Adv. 2018. PMID: 29991494 Free PMC article. Review.
-
Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study.Clin Lymphoma Myeloma Leuk. 2016 Mar;16(3):129-38. doi: 10.1016/j.clml.2015.12.007. Epub 2015 Dec 21. Clin Lymphoma Myeloma Leuk. 2016. PMID: 26795075 Free PMC article. Clinical Trial.
-
Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma.Leukemia. 2016 Oct;30(10):2026-2031. doi: 10.1038/leu.2016.123. Epub 2016 May 2. Leukemia. 2016. PMID: 27133826
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous